StreetAlpha.app
Home › Stocks › BDTX

Black Diamond Therapeutics, Inc. (BDTX)

Healthcare
$1.31
▼ −5.76%
LAST CLOSE · NOV 20

Black Diamond Therapeutics develops cancer drugs that target families of related gene mutations in patients with tumors. It last closed at $1.31 on Nov 20, down 5.76% on the day. The next earnings report for BDTX is expected around Mon, Mar 15, 2027, after the close. For the quarter ended Sep 2026, BDTX reported EPS of -$0.17 on revenue of $0. Over its last 8 reports the stock moved an average of 7.0% the session after earnings.

AI Auto Pilots
Is BDTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BDTX.

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$44.1M
−305.0% vs a year ago
EPS (diluted)
−$0.76
−305.4% vs a year ago
Valuation
Market cap
$75.3M
57.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$15.1M
At Sep 30
Shareholder equity
$88.1M
Shares outstanding
57.5M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $70.0M$70.0MFY2025

From BDTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · After the close
Reported EPS
-$0.17
Quarter ended Sep 2026
Year ago EPS
-$0.15
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.28Dec '24Mar 2025: $0.98Mar '25Jun 2025: -$0.19Jun '25Sep 2025: -$0.15Sep '25Dec 2025: -$0.26Dec '25Mar 2026: -$0.16Mar '26Jun 2026: -$0.17Jun '26Sep 2026: -$0.17Sep '26Latest -$0.17
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $70.0MMar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How BDTX moved after its last 8 reports
Average move the session after a report ±7.0%
Nov 10, 2026Time not announced−14.3%
Aug 5, 2026After the close+7.3%
May 7, 2026Time not announced−3.5%
Mar 16, 2026After the close+1.8%
Nov 6, 2025Time not announced+2.8%
Aug 7, 2025Time not announced−15.2%
May 12, 2025After the close+10.3%
Mar 6, 2025After the close−1.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BDTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BDTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BDTX

Technical Analysis

BDTX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 26% below its 20 day and 37% below its 50 day average. It is 62% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $1.28, and the nearest resistance the Pivot at $1.34.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.2%/day
Key levels
$4.0552 week high+209.2%
$2.12200 day average+61.8%
$1.90Swing high (Jul 22)+45.0%
$1.88100 day average+43.5%
$1.7950 day average+36.6%
$1.6520 day average+26.0%
$1.38Pivot R1+5.3%
$1.34Pivot+2.3%
$1.3152 week low+0.0%
$1.31Last close
$1.28Pivot S1−2.3%
Indicators
RSI (14)33.00Weak, oversold below 30Neutral
MACD-0.13Below its signal lineBearish
Stochastic4.5Near the bottom of its rangeOversold
ADX (14)21.9Weak trend
Williams %R-100.0Oversold below −80, overbought above −20Oversold
CCI (20)-140.8Oversold below −100, overbought above 100Oversold
Rate of change−24.5%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 10.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BDTX

What happened before

See how BDTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BDTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BDTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BDTXHow many large options trades hit BDTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

BDTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲64 buying vs 37 selling
  • ▲Held by funds +5.0 pts
  • ▲Funds holding +15
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding11196+15.6%
In funds' top 1000–
Held by funds66.0%61.0%+5.0 pts
New / increased24 / 4025 / 35+6.7%
Reduced / sold out26 / 1124 / 32−33.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BDTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BDTX Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 19, 2025Growth N V Biotech10% ownerSale5,784,292$2.07$12.0M
Every insider buy and sale for BDTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BDTX insider trades →

From SEC Form 4 filings by BDTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BDTX is in one of them and how their past BDTX trades turned out.

BDTX in the AI portfolios
Loading…

BDTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BDTX in an article yet. Here's the latest on the wider market.

BDTX in the news

About Black Diamond Therapeutics

Black Diamond Therapeutics is a drug developer based in Cambridge, Massachusetts. It develops cancer medicines designed to block families of related gene mutations rather than a single mutation, aiming to treat patients whose tumors have limited treatment options. Its lead candidate, silevertinib, is being tested in patients with lung cancer and brain tumors. The company has also licensed another candidate to Servier, which is developing it for cancer and genetic diseases.

Headquarters
Cambridge, MA